Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach.

P Fenn1, A Gray

  • 1The Business School, University of Nottingham, England. Paul.Fenn@nottingham.ac.uk

Pharmacoeconomics
|October 28, 1999
PubMed
Summary

This study models long term cost savings for Alzheimer's disease (AD) treatment. Early-stage treatment yields greater savings, but moderate-stage treatment is more cost-effective for shorter time horizons.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug management of TB in the intensive care setting: an international multicentre study.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction.

ESC heart failure·2024
Same author

Patient evaluation of Klick, a technology-enabled, nurse-delivered HIV outpatient pathway.

HIV medicine·2024
Same author

The societal economic impact of vision impairment in adults 40 years and above: findings from the National Eye Survey of Trinidad and Tobago.

Eye (London, England)·2023
Same author

Urgent appeal to allow all professional nurses and midwives to prescribe pre-exposure prophylaxis (PrEP) in South Africa.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2023
Same author

Proactive care post-discharge to reduce 30 day readmissions to hospital.

The International journal of risk & safety in medicine·2022

Area of Science:

  • Health Economics
  • Neuroscience
  • Clinical Trials

Background:

  • Alzheimer's disease (AD) poses a significant economic burden.
  • Estimating long-term cost savings from AD treatments is challenging due to limited data.

Purpose of the Study:

  • To propose a modelling approach for estimating long-term cost savings associated with Alzheimer's disease treatment.
  • To assess the impact of treatment on delaying disease progression and associated costs.

Main Methods:

  • Developed a model defining disease progression using Mini-Mental State Exam (MMSE) intervals.
  • Utilized clinical trial data from 1333 patients to determine time to more severe disease stages.
  • Employed survival analysis to quantify treatment's effect on delaying costly disease stages.

Related Experiment Videos

Main Results:

  • Extrapolated 3-year cost savings with high-dose rivastigmine reached approximately 1100 Pounds per patient.
  • Identified mild-stage AD treatment (MMSE > 20) as yielding the largest long-term cost savings.
  • Found moderate-stage AD treatment (MMSE 11-20) more cost-effective for time horizons under 2 years.

Conclusions:

  • The proposed model offers a viable method for estimating AD treatment cost savings.
  • Extrapolation of results beyond original study parameters requires caution.
  • Further research is needed to validate long-term resource use and drug efficacy data.